Skip to main content
Year archive

PERCHERON THERAPEUTICS LIMITED — 2020 filings

All 60 regulatory filings released by PERCHERON THERAPEUTICS LIMITED (PER) in 2020, sourced directly from the official regulator.

60 Filings
2020 Period
2020 filings (60)
Filing Released Lang
2020 Annual General Meeting Presentation 15 pages 2.6MB
AGM Information
2020-12-17 English
Annual General Meeting Chairman's Address 2 pages 167.9KB
AGM Information
2020-12-17 English
Results of Annual General Meeting 2 pages 174.7KB
Declaration of Voting Results & Voting Rights Announcements
2020-12-17 English
EC grants Orphan Drug Designation for ATL1102 in DMD 2 pages 122.7KB
Regulatory Filings
2020-12-13 English
Receipt of R&D Tax Incentive payment 1 page 77.2KB
Capital/Financing Update
2020-12-07 English
Change of Director's Interest Notice (x 2) 4 pages 264.4KB
Director's Dealing
2020-12-02 English
Ceasing to be a substantial holder 3 pages 120.4KB
Regulatory Filings
2020-12-02 English
ANP to present at Several Upcoming Virtual Conferences 1
Regulatory Filings
2020-12-01 English
Appendix 2A and 708A notice 15 pages 411.2KB
Share Issue/Capital Change
2020-12-01 English
Antisense Therapeutics closes SPP oversubscribed 1
Capital/Financing Update
2020-11-29 English
Antisense Therapeutics to present at Australian Equities Day 1
Regulatory Filings
2020-11-26 English
Reminder - Antisense Therapeutics SPP Closing Date 1
Capital/Financing Update
2020-11-24 English
Antisense Therapeutics Dual lists on the FSE 2 pages 141.7KB
Capital/Financing Update
2020-11-22 English
ANP Share Purchase Plan Booklet 18 pages 931.3KB
Capital/Financing Update
2020-11-18 English
Becoming a substantial holder 3 pages 143.4KB
Major Shareholding Notification
2020-11-17 English
Appendix 2A and Cleansing Notice 15 pages 433.0KB
Capital/Financing Update
2020-11-16 English
Notice of Annual General Meeting/Proxy Form 19 pages 478.5KB
AGM Information
2020-11-16 English
ATL1102 Orphan Drug Designation from EMA 2 pages 82.3KB
Regulatory Filings
2020-11-10 English
Proposed issue of Securities - ANP 9 pages 38.0KB
Capital/Financing Update
2020-11-10 English
ANP raises A$7.3 million from Oversubscribed Placement 4 pages 220.7KB
Capital/Financing Update
2020-11-10 English
Investor Presentation 27 pages 6.5MB
Investor Presentation
2020-11-10 English
Trading Halt 2 pages 213.7KB
Regulatory Filings
2020-11-09 English
ANP to apply for dual listing on Frankfurt Stock Exchange 2 pages 148.2KB
Capital/Financing Update
2020-11-08 English
Annual Report 60 pages 3.7MB
Annual Report
2020-10-28 English
Appendix 4G and Corporate Governance Statement 18 pages 447.0KB
Governance Information
2020-10-28 English
ANP receives US FDA ODD for ATL1102 in DMD 2 pages 144.5KB
Regulatory Filings
2020-10-25 English
Pause in Trading 1 page 111.1KB
Regulatory Filings
2020-10-21 English
Trading Halt 2 pages 214.4KB
Regulatory Filings
2020-10-21 English
Quarterly Update and Appendix 4C 8 pages 291.0KB
Interim / Quarterly Report
2020-10-20 English
ATL1102 shows significant improvement vs external control 14 pages 1.7MB
Investor Presentation
2020-10-01 English
US FDA Grants RPDD to ATL1102 for the treatment of DMD 2 pages 152.2KB
Regulatory Filings
2020-09-29 English
Antisense to present new data at WMS Virtual Congress 2020 2 pages 150.0KB
Investor Presentation
2020-09-28 English
Trading Halt 2 pages 132.5KB
Regulatory Filings
2020-09-27 English
Ceasing to be a substantial holder 3 pages 133.3KB
Regulatory Filings
2020-09-21 English
ANP Submits EU Orphan Drug application for ATL1102 in DMD 2 pages 125.0KB
Regulatory Filings
2020-08-30 English
Appendix 4E and Full Year Statutory Accounts 72 pages 2.5MB
Annual Report
2020-08-25 English
ANP Submits US Orphan Drug application for ATL1102 in DMD 2 pages 126.8KB
Regulatory Filings
2020-08-02 English
Quarterly Update and Appendix 4C 7 pages 287.1KB
Interim / Quarterly Report
2020-07-30 English
EMA DMD Scientific Advice and Regulatory Process Update 3 pages 155.2KB
Regulatory Filings
2020-07-29 English
ANP to participate at 2020 PPMD Virtual Annual Conference 1
Regulatory Filings
2020-07-15 English
Appendix 2A 15 pages 300.3KB
Capital/Financing Update
2020-07-08 English
Proposed issue of Securities - ANP 5 pages 27.3KB
Capital/Financing Update
2020-07-07 English
ShareCafe Small Cap Hidden Gems Webinar Presentation 1
Investor Presentation
2020-06-24 English
ANP to Present at Webinar Hosted by PPMD in the US 1
Regulatory Filings
2020-06-16 English
Poster Presentation MDA Virtual Conference 2020 3 pages 180.4KB
Capital/Financing Update
2020-06-10 English
Trial Met Primary & Exceeded Secondary Endpoint Expectations 24 pages 2.2MB
Regulatory Filings
2020-05-20 English
Trading Halt 2 pages 227.3KB
Regulatory Filings
2020-05-19 English
Market Update 1 page 118.1KB
Regulatory Filings
2020-05-13 English
Antisense to present at NWR Virtual Health Network 2 pages 187.5KB
Investor Presentation
2020-04-30 English
Quarterly Update and Appendix 4C 7 pages 313.0KB
Interim / Quarterly Report
2020-04-20 English
Phase II DMD trial database lock and final results on track 2 pages 174.3KB
Regulatory Filings
2020-03-17 English
ATL1102 Phase II data to be presented at DMD Conference 2 pages 194.8KB
Regulatory Filings
2020-03-04 English
Half Yearly Report and Half Year Accounts 33 pages 2.5MB
Interim / Quarterly Report
2020-02-27 English
Appointment of US-based Consultant Medical Director 2 pages 148.5KB
Board/Management Information
2020-02-26 English
Results in DMD unlock value creation potential of ATL1102 2 pages 113.8KB
Capital/Financing Update
2020-02-05 English
Quarterly Update & Appendix 4C 7 pages 270.1KB
Interim / Quarterly Report
2020-01-29 English
ANP Presentation for SACHS 3rd Neuroscience Innovation Forum 24 pages 2.6MB
Investor Presentation
2020-01-12 English
ANP to Present at Neuroscience Innovation Forum in the US 2 pages 207.5KB
Regulatory Filings
2020-01-09 English
Appendix 3B and 708A notice 13 pages 541.4KB
Capital/Financing Update
2020-01-02 English
Antisense Therapeutics Limited - Listed Options raise $5.5M 2 pages 157.7KB
Capital/Financing Update
2020-01-02 English